Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Lucas

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Breast Cancer Research : BCR|May 24, 2024
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancerSamuel A Jacobs, Ying Wang, Jame Abraham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2024
Machine Learning Predicts Oxaliplatin Benefit in Early Colon CancerLujia Chen, Ying Wang, Chunhui Cai, et al.
Hypertension (Dallas, Tex. : 1979)|September 4, 2014
Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodelingLajos Markó, Norbert Henke, Joon-Keun Park, et al.
NPJ Breast Cancer|July 3, 2019
FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtypeKevin M Levine, Nolan Priedigkeit, Ahmed Basudan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 TrialPriya Rastogi, Hanna Bandos, Peter C Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2025
Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon CancerLujia Chen, Ying Wang, Chunhui Cai, et al.
Breast Cancer Research : BCR|April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancerSamuel A Jacobs, Ying Wang, Jame Abraham, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppressionJuliana Hofstätter Azambuja, Saigopalakrishna S Yerneni, Lisa M Maurer, et al.
Cell Reports|September 30, 2016
MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD CleavageLinda R Klei, Dong Hu, Robert Panek, et al.
Journal for Immunotherapy of Cancer|October 20, 2019
Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumorsLi Zhu, Jessica L Narloch, Sayali Onkar, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Breast Cancer Research : BCR|May 24, 2024
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancerSamuel A Jacobs, Ying Wang, Jame Abraham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2024
Machine Learning Predicts Oxaliplatin Benefit in Early Colon CancerLujia Chen, Ying Wang, Chunhui Cai, et al.
Hypertension (Dallas, Tex. : 1979)|September 4, 2014
Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodelingLajos Markó, Norbert Henke, Joon-Keun Park, et al.
NPJ Breast Cancer|July 3, 2019
FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtypeKevin M Levine, Nolan Priedigkeit, Ahmed Basudan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 TrialPriya Rastogi, Hanna Bandos, Peter C Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2025
Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon CancerLujia Chen, Ying Wang, Chunhui Cai, et al.
Breast Cancer Research : BCR|April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancerSamuel A Jacobs, Ying Wang, Jame Abraham, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppressionJuliana Hofstätter Azambuja, Saigopalakrishna S Yerneni, Lisa M Maurer, et al.
Cell Reports|September 30, 2016
MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD CleavageLinda R Klei, Dong Hu, Robert Panek, et al.
Journal for Immunotherapy of Cancer|October 20, 2019
Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumorsLi Zhu, Jessica L Narloch, Sayali Onkar, et al.
Pageof 12